S WÛ

# World Journal of Gastrointestinal Surgery

Submit a Manuscript: https://www.f6publishing.com

World J Gastrointest Surg 2024 November 27; 16(11): 3425-3436

DOI: 10.4240/wjgs.v16.i11.3425

ISSN 1948-9366 (online)

ORIGINAL ARTICLE

#### **Retrospective Cohort Study**

## Proposal for a new classification of anorectal abscesses based on clinical characteristics and postoperative recurrence

Shan-Zhong Chen, Kui-Jun Sun, Yi-Fan Gu, Hong-Yuan Zhao, Dong Wang, Yun-Fang Shi, Ren-Jie Shi

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification Scientific Quality: Grade B, Grade C

Novelty: Grade B, Grade C Creativity or Innovation: Grade B, Grade C Scientific Significance: Grade B, Grade C

P-Reviewer: Tantau AI; Wang C

Received: June 29, 2024 Revised: September 12, 2024 Accepted: September 23, 2024 Published online: November 27. 2024 Processing time: 122 Days and 22.7

Hours



Shan-Zhong Chen, Ren-Jie Shi, First Clinical Medical College, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China

Shan-Zhong Chen, Kui-Jun Sun, Yi-Fan Gu, Hong-Yuan Zhao, Department of Anorectal Surgery, People's Hospital of Yangzhong, Zhenjiang 212200, Jiangsu Province, China

Dong Wang, Department of Ultrasound Medicine, People's Hospital of Yangzhong, Zhenjiang 212200, Jiangsu Province, China

Yun-Fang Shi, Department of Medical Imaging, People's Hospital of Yangzhong, Zhenjiang 212200, Jiangsu Province, China

Ren-Jie Shi, Department of Colorectal Surgery, Jiangsu Province Hospital of Chinese Medicine, Nanjing 210029, Jiangsu Province, China

Corresponding author: Ren-Jie Shi, MD, Chief Doctor, Professor, First Clinical Medical College, The Affiliated Hospital of Nanjing University of Chinese Medicine, No. 155 Hanzhong Road, Nanjing 210029, Jiangsu Province, China. 949194350@qq.com

### Abstract

#### BACKGROUND

Current surgical procedures for anorectal abscesses, including incision and drainage alone or combined concurrent fistulotomy, remain controversial primarily due to the unpredictability of postoperative recurrence or the progression to anal fistula.

#### AIM

To evaluate factors that predict postoperative recurrence of anorectal abscesses and propose a new classification to guide surgical procedures.

#### **METHODS**

In this retrospective study, 525 patients with anorectal abscesses treated by incision and drainage alone, at a tertiary general hospital from August 2012 to July 2022, were included. A new classification for anorectal abscesses based on their propensity to develop into fistulas, considering 18 other potential risk factors, was established. These factors, from electronic medical records, were screened for significance using the  $\chi^2$  test and subsequently analyzed with multivariate logistic regression to evaluate their relationship with postoperative



WJGS https://www.wjgnet.com

recurrence of anorectal abscesses.

#### RESULTS

One year post-follow-up, the overall recurrence rate was 39%:81.0% and 23.5% for fistula-prone and non-fistulaprone abscesses, respectively. Univariate  $\chi^2$  analysis showed significant differences in recurrence rates based on anatomical classifications and pus culture results (P < 0.05). Fistula-prone abscess,  $\geq 7$  days between symptom onset and surgery, chronic diarrhea, preoperative antibiotic use, and local anesthesia were risk factors for recurrence, while diabetes mellitus was protective (P < 0.05). Moreover, fistula-prone abscess [odds ratio (OR) = 7.651, 95% CI: 4.049–14.458, *P* < 0.001], ≥ 7 days from symptom onset to surgery (OR = 2.137, 95% CI: 1.090–4.190, *P* = 0.027), chronic diarrhea (OR = 2.508, 95% CI: 1.216–5.173, *P* = 0.013), and local anesthesia (OR = 2.308, 95% CI: 1.313–4.059, P = 0.004) were independent risk factors for postoperative anorectal abscess recurrence using multivariate logistic regression. Body mass index  $\geq$  28 (OR = 2.935, 95% CI: 1.203–7.165, P = 0.018) was an independent risk factor for postoperative recurrence of non-fistula-prone abscess.

#### CONCLUSION

The choice of surgical procedure for treating anorectal abscesses should follow this new classification. Prompt and thorough incision and drainage can significantly reduce postoperative recurrence.

Key Words: Anorectal abscess; New classification; Clinical characteristics; Risk factors; Postoperative recurrence rate; Surgical procedure

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This retrospective study evaluated the predictive factors for postoperative anorectal abscess recurrence and proposed a new classification to guide surgical procedures, including incision and drainage alone or a combined concurrent fistulotomy. We found that the recurrence rate of fistula-prone and non-fistula-prone abscesses (FPAs) was 81.0% and 23.5%, respectively. Additionally, we demonstrated that FPAs, a duration  $\geq$  7 days from symptom onset to surgery, chronic diarrhea, and local anesthesia were independent risk factors for postoperative anorectal abscess recurrence. Our findings support using this new classification to guide the choice of surgical procedures for treating anorectal abscesses.

Citation: Chen SZ, Sun KJ, Gu YF, Zhao HY, Wang D, Shi YF, Shi RJ. Proposal for a new classification of anorectal abscesses based on clinical characteristics and postoperative recurrence. World J Gastrointest Surg 2024; 16(11): 3425-3436 URL: https://www.wjgnet.com/1948-9366/full/v16/i11/3425.htm DOI: https://dx.doi.org/10.4240/wjgs.v16.i11.3425

#### INTRODUCTION

Anorectal abscesses are among the most common conditions encountered in the Department of Anorectal Surgery, with an estimated annual incidence of 68000-96000 in the United States<sup>[1]</sup>. Predominantly, in 90% of cases, anorectal abscesses develop due to cryptoglandular infections and can spread in multiple directions, leading to various types of abscesses[2]. In severe cases, the condition can progress to life-threatening necrotizing fasciitis<sup>[3]</sup>.

Undoubtedly, anorectal abscesses require surgical treatment; however, only a proportion of patients with this condition develop postoperative fistulas and it is difficult to predict. The choice between incision and drainage (I and D) alone or combined concurrent fistulotomy remains highly controversial. Proponents of the combined procedure argue that, based on the cryptoglandular infection theory, most anorectal abscesses would inevitably recur or develop anal fistulas after I and D alone, which can only be prevented by I and D combined with concurrent fistulotomy, thus avoiding reoperation<sup>[4-6]</sup>. Opponents argue that many anorectal abscesses treated with I and D alone do not recur or develop anal fistulas and that adding concurrent fistulotomy is unnecessary. They caution against damaging the anal sphincter or causing anal incontinence out of fear of a possible clinical prognosis. In addition, during the acute abscess phase, tissue edema and unclear anatomy increase the risk of artificially creating a false tract when searching for an internal opening, which can also predispose a patient to recurrence [7-9]. These guidelines advise against probing for a possible fistula at the abscess stage to avoid iatrogenic injury<sup>[10]</sup>. Current guidelines from the American Society of Colon and Rectal Surgeons have not reached a definitive conclusion on this issue[11]. Although the preoperative classification of patients with anorectal abscesses based on relapse tendency can guide surgical decision-making, there are few universally accepted doctrines on this subject.

Currently, anorectal abscesses are described according to their anatomical locations: (1) Ischiorectal; (2) Intersphincteric; (3) Supralevator; and (4) Submucosal abscesses[12]. While this provides guidance on the operative route it does not determine whether I and D alone or combined concurrent fistulotomy should be employed. This suggests an urgent need for a more effective strategy for the preoperative and intraoperative classification of anorectal abscesses according to their relapse tendency, thereby guiding the selection of the optimal surgical procedure to achieve a balance between



WJGS | https://www.wjgnet.com

recurrence prevention and function protection.

Through years of clinical observation, we found that fistula-prone abscesses (FPAs) have an extremely high rate of recurrence or fistula formation after simple I and D, while non-FPAs (NFPAs) exhibit a substantially lower rate of recurrence. This suggests that this new classification of anorectal abscesses is reasonable. Therefore, this retrospective study was conducted to test this hypothesis and provide the basis for this new classification. Furthermore, we aimed to identify other risk factors that might predict recurrent anorectal abscess to guide the choice of surgical procedure.

#### MATERIALS AND METHODS

#### General information

This study was approved by the Ethics Committee of Yangzhong People's Hospital (No. KY202317), and the requirement for written informed consent was waived due to its retrospective and anonymous nature.

Clinical data from outpatients and inpatients diagnosed with anorectal abscesses, treated with I and D alone in our hospital (a tertiary general hospital) from August 2012 to July 2022, were collected.

#### Inclusion and exclusion criteria

The inclusion criteria were as follows: (1) Patients diagnosed with an anorectal abscess, not limited by sex; (2) Patients with ages ranging from 18–70 years; and (3) Patients who underwent I and D alone at our hospital.

The exclusion criteria were as follows: (1) A non-cryptoglandular anorectal abscesses (caused by specific infection or trauma); (2) History of anal fistula and anorectal surgery; (3) Comorbidities including human immunodeficiency virus, malignant tumors, tuberculosis, inflammatory bowel disease, and necrotizing fasciitis; (4) Missing or incomplete clinical data; and (5) Pregnant patients.

Finally, 525 patients were enrolled in the study (Figure 1).

#### Definition of FPA

An fistula-prone abscess (FPA) is defined by several criteria: (1) It is characterized by a hard nodule, depression, or defect at the dentate line or sclerotic tissue between the pus cavity and the anal canal, as detected by a finger touch (characteristics of anorectal clinical examination); (2) During surgery, pus oozes from the corresponding area when pressing the pus cavity or liquid overflows when hydrogen peroxide and methylene blue are instilled into the pus cavity (characteristics of surgery); and (3) Ultrasound or magnetic resonance imaging (MRI) reveals an abscess cavity leading to the anal canal, internal sphincter involvement, or discontinuity (characteristics of imaging). If any of the above conditions are satisfied, it is classified as an FPA; otherwise, it is classified as a non-FPA (NFPA) (Figure 2).

#### Treatment strategy

All patients completed a routine preoperative examination to rule out contraindications to surgery and underwent ultrasound or MRI. Additionally, their medical histories, including multiple potential risk factors, were obtained. The sites of the anorectal abscesses and anatomical classifications were recorded.

Patients with perianal abscesses were divided into two groups based on the assessment of their conditions and patient preference: I and D was performed under outpatient local anesthesia or inpatient spinal anesthesia. Patients with other anatomical types of anorectal abscesses were hospitalized and received I and D under spinal anesthesia.


All surgeries were performed by the same experienced surgical team of attending or chief surgeons. First, anorectal clinical examinations were conducted, followed by pressing the pus cavity to check for any oozing pus. If this process failed, a small incision was made at the point of maximal bulge to drain the pus, and the pus volume was recorded. Subsequently, hydrogen peroxide was instilled with methylene blue into the pus cavity to observe whether any liquid overflowed. Notably, that there were some differences in the surgical approaches to different anatomical types. For perianal and ischiorectal abscesses, a radial incision was made at the point of maximal bulge. Necrotic tissues was removed, narrow skin edges were excised, and potential loculations were explored and opened. The abscess cavity was washed with dilute iodophor and saline, followed by dressing after achieving hemostasis. Additional counter incisions were made for horseshoe abscesses to ensure adequate drainage. For intersphincteric abscesses, partial internal sphincterotomy was performed to drain endoanally or transrectally. For supralevator abscesses, if secondary to an intersphincteric space infection, a partial internal sphincterotomy was performed to facilitate transrectal drainage and a drain tube was inserted into the supralevator space; if the infection originated from ischiorectal space, a transdermal incision and tube drainage was adopted. Probe was not used in anorectal abscess surgery to avoid creating false tracts and inadvertently destroying the local barrier.


The pus was cultured. Antibiotics were administered intravenously for 1-2 days postoperatively. Sitz baths were administered twice a day, and the dressing was changed once a day until the wounds healed.

#### Follow-up

The patients were instructed to visit the outpatient clinic immediately if they experienced any discomfort, such as perianal swelling and pain or pus discharge, after wound healing. If they remained asymptomatic, a follow-up was scheduled in the outpatient clinic 6 months and 1 year postoperatively, supplemented with telephone interviews. The study's primary endpoint was recurrence, defined as abscess relapse or fistula formation. A team of experienced anorectal surgeons judged recurrence based on a clinical exam and an ultrasound or MRI examination.










Figure 2 Clinical characteristics of fistula-prone abscess. A: There is a hard nodule, a depression, even a defect at the dentate line; B: Sclerotic tissue between the pus cavity and the anal canal by a finger touch; C: Pus oozes out of the corresponding area when press the pus cavity (direction of the yellow arrow); D: Liquid overflows when instilling hydrogen peroxide + methylene blue into the pus cavity during the operation (direction of the yellow arrow); E: Abscess cavity leading to the anal canal, internal sphincter involvement or discontinuity (direction of the yellow arrow in the ultrasound imaging); F: Abscess cavity leading to the anal canal, internal sphincter involvement or discontinuity (direction of the yellow arrow in the magnetic resonance imaging).

#### Statistical analysis

The original data were extracted from the electronic medical records and stored in Microsoft Excel; Statistical Package for the Social Sciences 26.0 software was used for statistical analysis. Categorical data were expressed as numbers (*n*) and percentage (%). Comparisons between groups were performed using the  $\chi^2$  test, and differences were defined as statistically significant at *P* < 0.05. A multivariate logistic regression analysis included the screened positive variables to explore the relationship between postoperative recurrence of anorectal abscesses and various factors. The same statistical approach was implemented in the NFPA subgroup.

Raishideng® WJGS | https://www.wjgnet.com

#### RESULTS

#### General information about the subjects

A total of 966 patients with anorectal abscesses were operated on in our hospital from August 2012 to July 2022. Among them, 712 patients underwent I and D alone, and 187 patients met the exclusion criteria. Consequently, 525 patients were enrolled in the study; 464 were male, and 61 were female, with this condition most prevalent among those aged 30-59 years. The most common anatomical classification was perianal (n = 322, 61.3%), followed by intersphincteric abscesses (n= 94,17.9%). Regarding abscess sites, approximately half were posterior (n = 261, 49.7%) compared with anterior abscesses (n = 14, 2.7%). Among the 322 patients with perianal abscesses, 181 underwent outpatient surgeries under local anesthesia, while 141 were hospitalized and operated under spinal anesthesia. FPAs were identified in 142 patients (27.0%). After 1 year of follow-up, 205 patients experienced recurrence, 320 were cured, resulting in a 39.0% relapse rate. FPAs and NFPAs recurrence rates were 81.0% and 23.5%, respectively.

#### A univariate analysis of risk factors for postoperative recurrence of anorectal abscess

Based on clinical experience and previous literature, 19 factors were included in the study. Given that the number of factors may affect the final results of the analysis, we first conducted a univariate analysis using the  $\chi^2$  test; the results showed that the recurrence rate was significantly different among patients with different anatomic classifications and pus culture results (P < 0.05). FPA, a duration  $\ge 7$  days from symptom onset to surgery, chronic diarrhea, preoperative antibiotic use, and local anesthesia were risk factors for recurrence. Diabetes mellitus appeared to be a protective factor (P < 0.05). The differences in postoperative recurrence rates of anorectal abscesses between the groups when classified based on sex, age, body mass index (BMI), pus volume, smoking status, drinking and spicy food habits, fever, constipation, insomnia, and abscess site were not significant (P > 0.05). Data are presented in Table 1.

#### A multivariate logistic regression analysis of risk factors for postoperative recurrence of anorectal abscess

The eight statistically significant variables mentioned above were included in the multivariate logistic regression analysis as independent variables, with recurrence as the dependent variable (the variable assignment is shown in Table 2). The results, detailed in Table 3, identified the following independent risk factors for postoperative recurrence of anorectal abscesses: FPA [odds ratio (OR) = 7.651, 95% CI: 4.049–14.458, P < 0.001], time  $\geq$  7 days from symptom onset to surgery (OR = 2.137, 95%CI: 1.090-4.190, P = 0.027), chronic diarrhea (OR = 2.508, 95%CI: 1.216-5.173, P = 0.013), and local anesthesia (OR = 2.308, 95%CI: 1.313-4.059, P = 0.004).

#### A univariate analysis of risk factors for postoperative recurrence in the NFPA subgroup

The FPA group could not be analyzed because the sample size was too small to satisfy the conditions for applying statistical methods. Univariate analysis of the risk factors for postoperative recurrence in the NFPA subgroup was performed using the  $\chi^2$  test, and the results showed that the recurrence rate differed significantly among patients with different anatomical classifications (P < 0.05). A BMI  $\ge 28$ , time  $\ge 7$  days from symptom onset to surgery, chronic diarrhea, and local anesthesia were risk factors for recurrence (P < 0.05). None of the remaining 13 factors significantly influenced the recurrence rate (P > 0.05). Details are presented in Table 4.

#### A multivariate logistic regression analysis of risk factors affecting postoperative recurrence of NFPAs

The five statistically significant variables mentioned above and pus volume were included in the multivariate logistic regression analysis as independent variables, with recurrence as the dependent variable (the variable assignment is shown in Table 5). The results are shown in Table 6. BMI ≥ 28 (OR = 2.935, 95% CI: 1.203–7.165, *P* = 0.018), time ≥ 7 days from symptom onset to surgery (OR = 5.978, 95% CI: 2.043–17.489, P = 0.001), chronic diarrhea (OR = 3.417, 95% CI: 1.388–8.412, *P* = 0.008), and local anesthesia (OR = 3.341, 95%CI: 1.565–7.133, *P* = 0.002) were identified as independent risk factors for postoperative recurrence of NFPAs.

#### DISCUSSION

In the current study, 39.0% of patients reported recurrence, nearly consistent with findings from previous studies[13-15]. Among the 525 enrolled patients, 142 were classified and assigned to the FPA group and 383 to NFPA group. The recurrence rate significantly differed between the two groups: 81.0% and 23.5% for the FPA and NFPA groups, respectively. The significant difference in recurrence rates observed in our study explains the wide range of recurrence previously reported (21%-88%)[16].

The presence of FPAs was identified as a significant risk factor for recurrence, in both the univariate and multivariate analysis ( $\chi^2$  = 143.842, OR = 7.651). Possible explanations for this result could be related to the three clinical characteristics of FPAs, which all imply disruption of the local barrier and increased permeability. The internal sphincter plays an important role in maintaining this barrier. As inflammation spreads and destroys the integrity of the internal sphincter, it ultimately compromises the local barrier, facilitating the continual migration of the intestinal bacteria to the perianal space. Eventually, a fistula will inevitably persist. This suggests that intraoperative use of a probe to explore a potential fistula tract is inadvisable. The new classification is necessary for guiding the choice of surgical procedure (I and D alone or with concurrent fistulotomy): (1) In the case of NFPAs, a simple I and D is sufficient, thus avoiding unnecessary injuries; and (2) For FPAs, fistulotomy or seton placement can be attempted to prevent recurrence. Notably, 19% of FPAs



WJGS https://www.wjgnet.com

Non-distingion         Find by the distingion         27 (190)         43.842         <0.00	Table 1 A univariate analysis of risk facto	ors for postoperativ	ve recurrence, <i>n</i> (%)			
Bislapene abcess162158(a)27(19)16.954.900Non-indual-proce abcess3639(23)23(65)3Cander1158(03)24(12)0Cander224(12)6(40)12Ineale224(12)6(30)12Ineale1214(3)6(30)12Agromy1216(2)7(64)1420201216(2)7(24)1220301216(2)7(24)1220402016(2)2(2)1220301216(2)2(2)1220402016(2)2(2)122030201212122040201212122050201212122050202020121220502020202012205020202020122051202020202020512020202020205220202020202053202020202020542020202020205420202020202054202020202020542020202020205420202020 <th>Variables</th> <th>Total (<i>n</i> = 525)</th> <th>Recurrence (<i>n</i> = 205) (39%)</th> <th>Cured (<i>n</i> = 320) (61%)</th> <th>χ² value</th> <th>P value</th>	Variables	Total ( <i>n</i> = 525)	Recurrence ( <i>n</i> = 205) (39%)	Cured ( <i>n</i> = 320) (61%)	χ² value	P value
NameNa	New classification					
definition         definition <thdefinition< th="">         definition         definiti</thdefinition<>	Fistula-prone abscess	142	115 (81.0)	27 (19.0)	143.842	< 0.001
Male641808,9)24(42)0,090,72Fenda612(40,0)6(50,0)14Aq(veras)7612,04(20,0)7(63,0)1,849,7120-3012610,507(63,0)7(62,0)1120-30205(20,0)7(62,0)11120-3021010(23,0)210,7011120-3021010(23,0)210,7011120-30210210,0020,6020,802120-30210210,0020,6020,802121-30210210,0020,7020,902121-30210210,0020,9020,902121-30210210,0020,9020,902121-30210210,0020,9020,902121-3021020,9020,9021121-3021020,9020,9021121-30210210,9020,9021121-30210210,9020,9021121-30210210,9020,9021121-30210210,9020,9021121-30210210,9020,9021121-30210210,9020,9021121-3021	Non-fistula-prone abscess	383	90 (23.5)	293 (76.5)		
Image ParameterA genome (2000)A genome (2000)Age (ream)73 (42.9)4 (57.1)2-307124 (66.6)7 (63.4)2-301214 (66.6)74 (67.4)7.72-30125 (26.2)74 (57.5)7.82-30205 (26.2)74 (57.5)7.82-302012 (20.2)21 (20.7)9.92-302110 (23.2)21 (27.7)9.92-302074 (30.1)2.8 (30.1)9.92-302110 (20.2)2.8 (30.1)9.92-322074 (30.1)2.8 (30.1)7.92-322074 (30.1)2.8 (77.0)7.90.002-32189 (72.7)3.107.7)7.94.900.002-72189 (72.7)3.107.7)7.94.900.002-72189 (72.7)3.107.7)7.94.900.002-72189 (72.7)3.107.7)7.94.900.002-72189 (72.7)3.107.7)7.94.900.002-720.1010 (20.1)2.5 (20.1)1.950.952-720.102.5 (20.1)1.000.000.002-720.1010 (20.1)2.6 (20.1)1.950.102-820.102.6 (20.1)1.950.100.102-920.102.6 (20.1)1.950.100.102-920.102.1 (20.1)2.6 (20.1)1.952-9	Gender					
Age years         3 (42.9)         4 (57.1)           20.9         112         4 (56.6)         7 (65.4)           30.9         120         5 (42.6)         7 (65.5)         1.808         0.71           40.49         120         5 (42.6)         7 (65.5)         1.808         0.71           40.49         120         6 (35.5)         7 (62.5)         1.808         0.71           40.49         120         4 (36.5)         26 (61.5)         0.278         0.392           50         100         0.273         0.278         0.392         2.58         0.278         0.392         2.58         0.278         0.392         2.58         0.278         0.392         2.58         0.278         0.392         2.58         0.278         0.392         2.58         0.278         0.392         2.58         0.278         0.392         2.58         0.278         0.392         2.59         0.278         0.392         2.59         0.278         0.392         2.59         0.593         2.59         0.593         2.59         0.070         0.791         0.591         0.591         0.591         0.591         0.591         0.591         0.591         0.591         0.591         0.591	Male	464	180 (38.8)	284 (61.2)	0.109	0.742
<2078(29)4(7)20291124(06)7(03)30301265(40)7(63)180840-491295(42)7(63)180850501205(26)7(62)180850401206(75)7(62)180850401206(25)2020201012016(25)201922348018(85)26(4)202412017(10)27(10)7.4902525262020271218(27)3(23)100271218(27)3(23)100271218(27)3(23)100271218(27)3(23)100281218(27)3(23)100291218(27)25(0)100201218(27)25(0)100201218(27)3(23)100201218(27)3(23)10020121120100100201211201001002012112010010020121120100100201211603)2010020121120100100201211201001002012112010010020121120100100<	Female	61	25 (41.0)	36 (59.0)		
20-9012041 (a 66)7 (a 6.4)7 (a 7.4)30-301265 (4 0.5)7 (6 2.5)1.880.7140-401206 (3 7.5)7 (6 2.5)1.880.7150-501206 (3 7.5)7 (2 0.5)1.881.8850-5012010 (0.5)2 (6 0.5)1.880.5750-5012010 (0.5)2 (8 (0.5)0.720.5223600 (10 (0.5)2 (8 (0.5)0.720.52240410 (0.5)2 (8 (0.5)0.720.52571208 (7.7)2 (7.1)7 (9.0)7 (9.0)0.715712117 (20)2 (7.1)7 (9.0)0.710.715812110 (9.0)2 (7.1)0.720.720.715912110 (9.0)2 (9.0)0.710.710.715012112 (9.0)2 (9.0)0.720.710.715012112 (9.0)2 (9.0)1.720.710.715012112 (9.0)2 (9.0)1.720.710.715012112 (9.0)12 (9.0)1.720.720.715012112 (9.0)12 (9.0)1.721.721.725012112 (9.0)12 (9.0)1.721.721.725012112 (9.0)12 (9.0)1.721.721.725012112 (9.0)12 (9.0)1.721.721.7250<	Age (years)					
No.No.No.No.No.No.No.No.No.40-912955 (42.6)74 (57.4)75 (62.5)75 (62.5)75 (62.5)75 (62.5)75 (62.5)75 (62.5)75 (62.5)75 (62.5)75 (62.5)75 (62.5)75 (62.5)75 (75 (62.5)75 (75 (75 (75 (75 (75 (75 (75 (75 (75 (	< 20	7	3 (42.9)	4 (57.1)		
40-912954 (26)74 (27)50-5912045 (07.5)75 (62.5)> 603110 (23.3)21 (67.7)Body mas index (kg/m²) $x$ $x$ $x$ $< 23$ 9037 (16.6)268 (61.5)0.2782.89037 (16.6)268 (61.5)0.278 $< 23$ 9037 (16.6)268 (61.5) $x$ $< 23$ 9037 (16.6)268 (61.5) $x$ $< 7$ 404117 (29.0)267 (71.0)74.90 $x$ $< 7$ 12146 (88.0)75 (62.0)0.0700.791Snokar12146 (88.0)75 (62.0)0.0700.791Non smoker12146 (88.0)26 (60.6)10260.111Non smoker12146 (88.0)20 (61.2)10260.111Non smoker12146 (88.0)20 (61.2)0.0700.791Non smoker12146 (88.0)20 (61.2)10260.111No for dubit159 (39.4)50 (62.2)1.0260.111No for dubit150 (39.9)26 (60.1)102102Diabets multitus150 (29.9)20 (60.1)102102No2010 (20.2)27 (50.3)102102No120151 (15.9)40 (71.1)4.630.02No120151 (15.9)4.04 (13.1)10.6210.62No2010 (20.2)26 (90.1)102102No121161 (15.2)	20-29	112	41 (36.6)	71 (63.4)		
1000100010001000>60310.023)21.677Noty mass index (kg/m)2284961.68 (8.5)2.68 (6.5)0.2780.592>289037.(1.6)52 (58.4)22Time from symptom onsect o surgery (day)233.027.07.4940 $4.000$ >712188 (72.7)33.027.07.4940 $4.000$ 2712186 (72.7)33.027.00.070 $0.791$ Smoker1214.68.0075 (62.0)0.070 $0.791$ Ponkary tabuts1214.68.0175 (62.0) $0.070$ $0.791$ Smoker1214.68.0175 (62.0) $0.070$ $0.791$ Ponkary tabuts1214.68.0175 (62.0) $0.070$ $0.791$ No smoker1214.68.01270 (61.9) $0.791$ $0.791$ Ponkary tabuts1214.68.01200 (61.9) $0.170$ $0.592$ No36150 (99)256 (0.1) $0.170$ $0.592$ $0.592$ No36150 (99)256 (0.1) $0.170$ $0.592$ $0.692$ No46719 (40.7)27 (9.3) $0.791$ $0.791$ No12251 (14.8)71 (58.2) $0.072$ $0.791$ No12315 (15.9)4.5 (4.01) $0.691$ $0.692$ $0.691$ No12419 (10.0)25 (8.0) $0.17$ $0.592$ $0.012$ No12419 (10.2)25 (8.0) $0.17$ <td< td=""><td>30-39</td><td>126</td><td>51 (40.5)</td><td>75 (59.5)</td><td>1.808</td><td>0.771</td></td<>	30-39	126	51 (40.5)	75 (59.5)	1.808	0.771
	40-49	129	55 (42.6)	74 (57.4)		
Roly mass index (kg/m²)Since the form of the form of the form symptom onset to surgery (days)Since the form symptom onset to surgery (days) </td <td>50-59</td> <td>120</td> <td>45 (37.5)</td> <td>75 (62.5)</td> <td></td> <td></td>	50-59	120	45 (37.5)	75 (62.5)		
<28486168 (85)268 (615)0.2780.28≥ 28907(41.6)52 (8.4)5Ture from symptom onset to surgery (day)40417 (29.0)257 (71.0)74.905 (0.0)≥ 712186 (27.7)30 (7.3)760.0706≥ 712146 (8.0)75 (6.0)0.0700.0700.0710.071Smoker12146 (8.0)75 (6.0)0.0700.0700.071Non smoker404159 (39.4)25 (60.6)0.0210.011No smoker404159 (39.4)20 (61.9)0.0210.011No smoker43616 (38.1)20 (61.9)0.2880.288No3615 (36.9)44 (63.1)0.3980.288No3615 (25.9)45 (74.1)4.7630.021Pateet smellitus1214 (18.2)27 (59.3)14 (18.2)0.0710.071Fever1215 (45.2)21 (61.9)0.0710.07210 (19.0)10 (10.0)10 (10.0)No1215 (18.2)16 (30.1)26 (60.1)14 (10.0)16 (10.0)10 (10.0)10 (10.0)10 (10.0)10 (10.0)Fever1215 (18.2)16 (18.2)16 (18.0)16 (10.0)16 (10.0)16 (10.0)10 (10.0)10 (10.0)10 (10.0)10 (10.0)10 (10.0)No1216 (10.0)16 (10.0)16 (10.0)16 (10.0)16 (10.0)10 (10.0)10 (10.0)No	> 60	31	10 (32.3)	21 (67.7)		
28897 (4)52 (5)The form symptom onset to surgery (Jays)17 (29,0)287 (71,0)74,9406,000271218 (72,7)3 (27,3)10027Snoking status1214 (68,0)75 (62,0)0.0700.791Snoker1214 (68,0)75 (62,0)0.0700.791Non smoker404159 (39,4)25 (60,6)101102Dinking habit106 (68,1)20 (61,9)1020.311No3616 (68,1)20 (61,9)1020.528No3615 (59,9)4 (63,1)0.3980.528No3615 (59,9)26 (60,1)102102Diabetes mellitus19 (40,7)27 (59,3)102102Fever1910 (40,7)27 (59,3)102104No1225 (14,18)7 (58,2)0.5070.476No13116 (32,1)26 (60,1)102104Properative antibiotic use19114,18115114No3116 (32,0)25 (60,0)104104No31106 (20,0)25 (60,0)104105No31106 (20,0)25 (60,0)104105No131106 (20,0)25 (60,0)104105No131106 (20,0)25 (60,0)104105No131106 (20,0)25 (60,0)104105No104106 (20,0)25 (60,0) </td <td>Body mass index (kg/m<sup>2</sup>)</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Body mass index (kg/m <sup>2</sup> )					
The from symptom onset to surgery (days)         44         17 (200)         287 (710)         74.90         <0000           ≥ 7         121         8 (72.7)         33 (27.3)	< 28	436	168 (38.5)	268 (61.5)	0.278	0.592
$<7$ $404$ $117$ (20,0) $287$ (71,0) $74,940$ $<0.007$ $\geq 7$ $121$ $88$ (72,7) $33$ (27,3)Smoking status $121$ $46$ (38,0) $75$ (62,0) $0.070$ $0.791$ Non smoker $404$ $159$ (39,4) $245$ (60.6) $1026$ $0.171$ Drinking habit $192$ $943.8$ $50$ (56.2) $1.026$ $0.311$ No $894$ $39$ (43.8) $50$ (56.2) $1.026$ $0.311$ No $896$ $36(38,1)$ $270$ (61.9) $1026$ $0.311$ Spicy food habit $199$ $55$ (36.9) $94$ (63.1) $0.398$ $0.528$ No $376$ $156$ (39.9) $266$ (60.1) $1026$ $1029$ Diabetes mellitus $199$ $15(25.9)$ $413$ (74.1) $4.763$ $0.29$ No $467$ $190$ (40.7) $277$ (59.3) $1026$ $0.176$ Fever $122$ $5141.8$ $2196(1.8)$ $106.92$ $0.507$ $0.476$ No $403$ $154$ (38.2) $249$ (61.8) $10.567$ $0.007$ No $331$ $106$ (32.0) $256.80$ $10.72$ $0.597$ Ves $124$ $99$ (51.0) $256.80$ $10.72$ $0.507$ No $331$ $106$ (32.0) $256.80$ $10.72$ $0.507$ No $331$ $166.32.1$ $256.80$ $10.72$ $0.597$ No $331$ $106$ (32.0) $256.80$ $10.72$ $0.507$ No $331$ $106$ (32.0) $256.80$ $10.72$ <td< td=""><td>≥28</td><td>89</td><td>37 (41.6)</td><td>52 (58.4)</td><td></td><td></td></td<>	≥28	89	37 (41.6)	52 (58.4)		
$\geq 7$ 12188 (72.7)34 (27.3)Smoking status12146 (38.0)75 (62.0)0.0700.791Smoker12146 (38.0)75 (62.0)0.0700.791Non smoker404159 (39.4)245 (60.6)1020.311Drinking habit50 (56.2)1.0260.311No436166 (38.1)270 (61.9)10260.311No436159 (39.9)226 (60.1)10260.528No376150 (39.9)226 (60.1)10260.298No376150 (39.9)226 (60.1)10260.299No467190 (40.7)277 (59.3)10260.299No467190 (40.7)277 (59.3)10260.476No12251 (41.8)71 (58.2)0.5070.476No12316 (32.1)249 (61.8)10261000Properative antibiotic use1949 (51.0)95 (49.0)18.565<0.002	Time from symptom onset to surgery (days)					
Smoking status         121         46 (38.0)         75 (62.0)         0.070         0.791           Non smoker         404         19 (93.4)         245 (60.6)         1000         1000           Drinking habit         50 (56.2)         1.026         0.311         0.070         0.311           No         436         166 (38.1)         200 (61.9)         1000         0.258           Spicy food habit         55 (36.9)         94 (63.1)         0.398         0.528           No         376         150 (39.9)         266 (60.1)         1000           Diabetes mellitus         150 (39.9)         266 (00.1)         1000         1029           No         467         190 (40.7)         277 (59.3)         1000         1029           No         467         190 (40.7)         277 (59.3)         1000         1000           Prever         122         51 (41.8)         16 (82.0)         0.507         0.476           No         132         16 (38.2)         249 (61.8)         1000         1000           Preoperative antibiotic use         122         51 (41.8)         16 (39.0)         18.565         <0.002	<7	404	117 (29.0)	287 (71.0)	74.940	< 0.001
And         121         46 (38.0)         75 (62.0)         0.070         0.71           Non smoker         404         159 (39.4)         245 (60.6)         1         1           Drinking habit           39 (43.8)         50 (56.2)         1.026         0.31           No         436         166 (38.1)         200 (61.9)         1         1           Spicy food habit           149         55 (36.9)         94 (63.1)         0.398         0.528           No         376         150 (39.9)         226 (60.1)         1	≥7	121	88 (72.7)	33 (27.3)		
Non smoker         404         159 (39.4)         245 (60.6)           Drinking habit         - <td>Smoking status</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Smoking status					
Drinking habit         99         39 (43.8)         50 (56.2)         1.026         0.311           No         436         166 (38.1)         270 (61.9)         55           Spicy food habit         55 (36.9)         94 (63.1)         0.398         0.528           No         376         150 (39.9)         226 (60.1)         528           Diabetes mellitus         376         150 (39.9)         226 (60.1)         528           No         376         150 (39.9)         226 (60.1)         528           Diabetes mellitus         4763         10.29         100 (40.7)         276 (59.3)         528           No         467         190 (40.7)         277 (59.3)         528         10.29           No         122         51 (41.8)         71 (58.2)         0.507         0.476           No         122         51 (41.8)         249 (61.8)         550         0.007           Preoperative antibiotic use         124         54 (32.0)         256 (80.0)         50         0.007           No         310         106 (32.0)         25 (68.0)         50         0.007         9.50           Constipation         42         16 (88.1)         26 (61.9)         0.017	Smoker	121	46 (38.0)	75 (62.0)	0.070	0.791
Yes8939(43.8)50(5c.2)1.0260.31No436016(38.1)27(10.9)333Spicy food habit57573646(3.1)0.39855Yes14957 (30.9)26 (00.1)1055Dabetes mellitus5815 (39.9)26 (00.1)1010Yes5815 (25.9)43 (74.1)4.76.30.29No6710 (40.7)27 (59.3)1010Fever12251 (41.8)71 (58.2)0.5074.76No403154 (32.2)24 (61.8)1010Yes19496 1.0125 (80.0)15.554.002No3116 (32.0)25 (80.0)1010Yes19496 1.0125 (80.0)10.74.85No3116 (32.0)25 (80.0)15.554.002Yes4216 (81.1)26 (61.9)0.0176.85Yes4319 (93.1)24 (60.9)10.719.85	Non smoker	404	159 (39.4)	245 (60.6)		
Yes8939(43.8)50(5c.2)1.0260.31No436016(38.1)27(10.9)333Spicy food habit57573646(3.1)0.39855Yes14957 (30.9)26 (00.1)1055Dabetes mellitus5815 (39.9)26 (00.1)1010Yes5815 (25.9)43 (74.1)4.76.30.29No6710 (40.7)27 (59.3)1010Fever12251 (41.8)71 (58.2)0.5074.76No403154 (32.2)24 (61.8)1010Yes19496 1.0125 (80.0)15.554.002No3116 (32.0)25 (80.0)1010Yes19496 1.0125 (80.0)10.74.85No3116 (32.0)25 (80.0)15.554.002Yes4216 (81.1)26 (61.9)0.0176.85Yes4319 (93.1)24 (60.9)10.719.85	Drinking habit					
No436166 (38.1)270 (61.9)Spic food habit57 (36.9)94 (33.1)0.3980.328Yes14957 (36.9)26 (60.1)12Diabetes mellitus5815 (25.9)43 (74.1)4.7630.29No6710 (40.7)27 (59.3)1214Fever1251 (41.8)10 (52.3)14.7214.72No1251 (41.8)10 (52.0)0.5070.476No1251 (41.8)10 (50.1)14.7214.72No13116 (32.1)25 (68.0)1111Yes1496 (30.1)25 (68.0)1115.72Yes1216 (38.1)26 (61.9)0.0170.895No4318 (38.1)26 (61.9)0.0170.895	Yes	89	39 (43.8)	50 (56.2)	1.026	0.311
Yes         149         55 (36.9)         94 (63.1)         0.398         0.528           No         376         150 (39.9)         226 (60.1)         1         1           Diabetes mellitus         150 (39.9)         226 (60.1)         1<	No	436	166 (38.1)			
No         376         150 (39.9)         226 (60.1)           Diabetes mellitus         58         15 (25.9)         43 (74.1)         4.763         0.029           No         467         190 (40.7)         277 (59.3)         100 (27)         100 (27)           Fever         122         51 (41.8)         71 (58.2)         0.507         0.476           No         403         154 (38.2)         249 (61.8)         100 (20)         100 (20)           Preoperative antibiotic use         124         51 (41.8)         106 (32.0)         25 (68.0)         100 (25)           No         31         106 (32.0)         25 (68.0)         1017         0.895           Constipation         423         16 (38.1)         26 (61.9)         0.017         0.895	Spicy food habit					
No36150 (39.9)226 (60.1)Diabetes mellitus5852 (59.9)43 (74.1)4.630.029No64190 (40.7)27 (59.3)1.630.029Fever12251 (41.8)71 (58.2)0.5070.476No023154 (38.2)24 (61.8)0.5070.476Preoperative antibiotic use1949 (51.0)25 (68.0)1.63No3116 (32.0)25 (68.0)1.654.002Constipation12163.1)26 (61.9)0.0170.895No4318 (39.1)24 (60.9)0.0170.895	Yes	149	55 (36.9)	94 (63.1)	0.398	0.528
Diabetes mellitus       58       15 (25 9)       43 (74 1)       4.763       0.029         No       467       190 (40.7)       277 (59.3)       1       1         Fever       12       51 (41.8)       71 (58.2)       0.507       0.476         No       403       154 (38.2)       249 (61.8)       1       1         Preoperative antibiotic use       194       90 (51.0)       25 (68.0)       1       1         No       31       16 (32.0)       25 (68.0)       1	No	376	150 (39.9)			
No       467       190 (40.7)       277 (59.3)         Fever       122       51 (41.8)       71 (58.2)       0.507       0.476         No       403       154 (38.2)       249 (61.8)       0       0       0         Preoperative antibiotic use       194       99 (51.0)       95 (49.0)       18.565       < 0.007	Diabetes mellitus					
No       467       190 (40.7)       277 (59.3)         Fever       122       51 (41.8)       71 (58.2)       0.507       0.476         No       403       154 (38.2)       249 (61.8)       0       0       0         Preoperative antibiotic use       194       99 (51.0)       95 (49.0)       18.565       < 0.007	Yes	58	15 (25.9)	43 (74.1)	4.763	0.029
Fever       122       51 (41.8)       71 (58.2)       0.507       0.476         No       403       154 (38.2)       249 (61.8)       100       100         Preoperative antibiotic use       194       90 (51.0)       95 (49.0)       18.565       < 0.007	No					
Yes       122       51 (41.8)       71 (58.2)       0.507       0.476         No       403       154 (38.2)       249 (61.8)       100       100         Preoperative antibiotic use       194       90 (51.0)       95 (49.0)       18.565       < 0.007	Fever			× /		
No       403       154 (38.2)       249 (61.8)         Preoperative antibiotic use       194       99 (51.0)       95 (49.0)       18.565       < 0.007	Yes	122	51 (41.8)	71 (58.2)	0.507	0.476
Preoperative antibiotic use       194       99 (51.0)       95 (49.0)       18.565       < 0.007						
Yes       194       99 (51.0)       95 (49.0)       18.565       < 0.017         No       331       106 (32.0)       225 (68.0)       100 (2000)       100 (2				. ,		
No     331     106 (32.0)     225 (68.0)       Constipation     225 (61.9)     0.017     0.895       Yes     42     16 (38.1)     26 (61.9)     0.017     0.895       No     483     189 (39.1)     294 (60.9)     100 (000)	Yes	194	99 (51.0)	95 (49.0)	18.565	< 0.001
Constipation         Yes       42       16 (38.1)       26 (61.9)       0.017       0.895         No       483       189 (39.1)       294 (60.9)       11       11			. ,			
Yes         42         16 (38.1)         26 (61.9)         0.017         0.895           No         483         189 (39.1)         294 (60.9)         294 (60.9)						
No 483 189 (39.1) 294 (60.9)		42	16 (38.1)	26 (61.9)	0.017	0.895
					0.017	0.070
	Chronic diarrhea	100				

 Jaisbideng®
 WJGS
 https://www.wjgnet.com

No <th>Yes</th> <th>98</th> <th>61 (62.2)</th> <th>37 (37.8)</th> <th>27.242</th> <th>&lt; 0.001</th>	Yes	98	61 (62.2)	37 (37.8)	27.242	< 0.001
InstructKardina<					27.242	0.001
<table-row><table-row><table-row><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-row></table-row></table-row>		427	144 (33.7)	203 (00.3)		
<table-row><table-row><table-row><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-row></table-row></table-row>		84	25 (41 7)	40 (58 3)	0.288	0 501
AnsentierAnsentierAnsentierAnsentierAnsentierLocal18174 do.9107 (9.1)8.3050.044Spinal100.570.910.570.91Abscress rite14 (28.6)10 (7.1)0.5370.91Posterior2619 (36.4)16 (6.6).11Right122 (4.8)06 (6.2)11Antomic classification212 (4.8)06 (6.2)11Preinal2210 (4.2)7 (36.2)14.458<001			. ,		0.288	0.391
IcadIq </td <td></td> <td>441</td> <td>170 (38.5)</td> <td>271 (61.5)</td> <td></td> <td></td>		441	170 (38.5)	271 (61.5)		
<table-row><table-row><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-row></table-row>		101	74 (40.0)		8 205	0.004
<table-row><table-row><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row></table-row><table-row></table-row><table-row><table-row></table-row><table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-row></table-row>					8.305	0.004
Anerior1448.610.71.40.3370.91Poterior26.096.64.016.63.011Left2020.43.060.52.011Antonic classification1740.70.07.02.011Prinand21210.42.020.63.04.45.9<0.01		141	36 (25.5)	105 (74.5)		
Posterior26195 (36.4)164 (63.6)Left9232 (34.8)60 (65.2)Right174 (37.6)73 (62.4)Anatomic classification1253 (62.8)3.458Perianal322110 (32.1)212 (65.8)3.458Ichresphincteric9424 (25.5)70 (74.5)Ichrosphincteric6841 (60.3)27 (39.7)Ichrosphincteric8426.7)10 (26.3)Ichrosphincteric8426.7)10 (26.3)Ichrosphincteric1321.613.3)Ichrosphincteric140.0)12 (58.9)10.1Ichrosphincteric1313.7518.62.5)Ichrosphincteric14.0.2)12 (58.9)10.1Ichrosphincteric14.0.2)12 (58.9)10.1Ichrosphincteric13.113.7513.62.5)Ichrosphincteric13.113.113.1Ichrosphincteric14.0.2)14.0.214.0.2Ichrosphincteric14.114.0.214.0.2Ichrosphincteric14.114.0.214.0.2Ichrosphincteric14.114.0.214.0.2Ichrosphincteric14.114.0.214.0.2Ichrosphincteric14.114.0.214.0.2Ichrosphincteric14.114.0.214.0.2Ichrosphincteric14.114.0.214.0.2Ichrosphincteric14.114.0.214.0.2Ichrosphincteric14.114.0.214.0.2Ichrosphinct						
Iref9292(34)90(52)91(52)Right17436730(62)91(62)Antomic classification10210(32)212(65)43.45840.01Irensplinctric92425,5070(7)101101Irensplinctric84160,3010(2,30)101101Irensplinctric84267,3010(2,30)101101Irensplinctric160,30102,30101101101Irensplinctric110,7010(3,00)101101101Irensplinctric110101101101101Irensplinctric110101101101101Irensplinctric110101101101101Irensplinctric110101101101101Irensplinctric110101101101101Irensplinctric110101101101101Irensplinctric110101101101101Irensplinctric110101101101101Irensplinctric110101101101101Irensplinctric110101101101101Irensplinctric110101101101101Irensplinctric110101101101101Irensplinctric110101101101101Irensplinctric110101101101101<				. ,	0.537	0.911
<table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container>						
Anatomic classificationPerianal3210(32,000)34.38< 0.001		92	32 (34.8)	60 (65.2)		
PerianalB210 (42)21 (65)43.438< 0.001Indresphincteric9424 (25)70 (45)70 (45)70 (45)Ichioredal6841 (60.3)70 (37)70 (37)70 (37)Ibrosshoe3226 (37)10 (26.3)70 (45)70 (45)Supralevator3421 (37)10 (31)71 (45)Parodumentor131 (37)218 (62.5)100 (15)31 (15)Soft and the second seco	Right	117	44 (37.6)	73 (62.4)		
Intersphincteric9424 (25.9)70 (74.5)Ischiorectal6841 (60.3)27 (39.7)Ischiorectal6828 (73.7)10 (26.3)Supralevator326 (6.7)1 (33.3)Pus volume (mL) $   \leq 5$ 349131 (37.5)218 (62.5)1.001 $\geq 5$ 17674 (42.0)102 (58.0)Pus culture $  -$ With results23099 (43.0)131 (57.0)17.214 <i>Scherichia coli</i> 15476 (49.4)28 (62.2) <i>Kabylococcus aureus</i> 91.03.7 $-$ <i>Staphylococcus aureus</i> 91.03.8) $-$ <i>Staphylococcus aureus</i> 91.03.8) $-$ <i>Staphylococcus aureus</i> 91.03.9) $-$ <i>Staphylococcus aureus</i> 98.40.0) $ -$ <i>Staphylococcus aureus</i> 98.40.0) $ -$	Anatomic classification					
Ischiorectal6841 (60.3)27 (39.7)Horseshoe3828 (37.3)10 (26.3)Supralevator3126.7)10.3)Parodume (mL)53413 (37.5)18 (62.5)<5	Perianal	322	110 (34.2)	212 (65.8)	43.458	< 0.001
Horseshoe3828 (73.7)10 (26.3)Supralevator32 (66.7)1 (33.3)Pusvolume (mL) $$	Intersphincteric	94	24 (25.5)	70 (74.5)		
Supralevator362667103.3Provolume (mL)	Ischiorectal	68	41 (60.3)	27 (39.7)		
Pus volume (mL)       >131 (37.5)       218 (62.5)       1.001       0.317         ≥ 5       176       74 (42.0)       102 (58.0)          Pus culture             With results       230       99 (43.0)       131 (57.0)       17.214       0.002         Escherichia coli       154       76 (49.4)       78 (50.6)           Klebsiella pneumoniae       37       14 (37.8)       23 (62.2)           Others       20       8 (40.0)       12 (60.0)	Horseshoe	38	28 (73.7)	10 (26.3)		
$<5$ $349$ $131$ (37.5) $218$ (62.5) $1.001$ $0.317$ $\geq 5$ $176$ $742.0$ $102$ (58.0) $17.214$ $17.214$ $0.021$ Pus culture $230$ $9(43.0)$ $131$ (57.0) $17.214$ $0.002$ Escherichia coli $154$ $76$ (49.4) $28$ (50.6) $14.21$ $14.21$ Klebsiella pneumoniae $37$ $14.37.8$ $23.62.2$ $14.21$ $14.21$ Staphylococcus aureus $19$ $15.31$ $18.94.7$ $14.21$ $14.21$ Others $20$ $8.40.0$ $21.60.0$ $14.21$ $14.21$	Supralevator	3	2 (66.7)	1 (33.3)		
≥5       176       74 (42.0)       102 (58.0)         Pus culture       230       99 (43.0)       131 (57.0)       17.214       0.002         Kebsiella pneumoniae       154       76 (49.4)       78 (50.6)       14       75.0       17.214       0.002         Staphylococcus aureus       17.21       14.07.8)       23 (62.2)       14       14       14.07.8)         Others       20       8 (40.0)       12 (60.0)       14.07.8)       12.00.1       14.07.8)	Pus volume (mL)					
Pus cultureWith results23099 (43.0)131 (57.0)17.2140.002Escherichia coli15476 (49.4)78 (50.6)1478Klebsiella pneumoniae3714 (37.8)23 (62.2)14Staphylococcus aureus191 (5.3)18 (94.7)14Others208 (40.0)12 (60.0)14	< 5	349	131 (37.5)	218 (62.5)	1.001	0.317
With results23099 (43.0)131 (57.0)17.2140.002Escherichia coli15476 (49.4)78 (50.6)78 (50.6)Klebsiella pneumoniae3714 (37.8)23 (62.2)14 (51.2)Staphylococcus aureus1915.3)18 (94.7)14 (50.6)Others208 (40.0)12 (60.0)14 (50.6)	≥5	176	74 (42.0)	102 (58.0)		
Escherichia coli       154       76 (49.4)       78 (50.6)         Klebsiella pneumoniae       37       14 (37.8)       23 (62.2)         Staphylococcus aureus       19       1 (5.3)       18 (94.7)         Others       20       8 (40.0)       12 (60.0)	Pus culture					
Klebsiella pneumoniae     37     14 (37.8)     23 (62.2)       Staphylococcus aureus     19     1 (5.3)     18 (94.7)       Others     20     8 (40.0)     12 (60.0)	With results	230	99 (43.0)	131 (57.0)	17.214	0.002
Staphylococcus aureus         19         1 (5.3)         18 (94.7)           Others         20         8 (40.0)         12 (60.0)	Escherichia coli	154	76 (49.4)	78 (50.6)		
Others         20         8 (40.0)         12 (60.0)	Klebsiella pneumoniae	37	14 (37.8)	23 (62.2)		
	Staphylococcus aureus	19	1 (5.3)	18 (94.7)		
No growth 295 106 (35.9) 189 (64.1)	Others	20	8 (40.0)	12 (60.0)		
	No growth	295	106 (35.9)	189 (64.1)		

Table 2 Variable assignment table of risk factors					
Variables	Assignment				
Postoperative prognosis	1: Recurrence, 0: Cured				
New classification	1: Fistula-prone abscess, 0: Non-fistula-prone abscess				
Time from symptom onset to surgery (days)	$1: \ge 7, 0: < 7$				
Diabetes mellitus	1: Yes, 0 : No				
Preoperative antibiotic use	1: Yes, 0: No				
Chronic diarrhea	1: Yes, 0: No				
Anesthesia method of perianal abscess	1: Local, 0: Spinal				
Anatomic classification	1: Perianal, 2: Intersphincteric, 3: Ischiorectal, 4: Horseshoe, 5: Supralevator				
Pus culture	1: Escherichia coli, 2: Klebsiella pneumoniae, 3: Staphylococcus aureus, 4: Others, 0: No results				

Saisbideng® WJGS | https://www.wjgnet.com

Table 3 A multivariate logistic regression analysis of risk factors for postoperative recurrence								
Variables	B value	SE	Wald	P value	Odds ratio	95%CI		
New classification	2.035	0.325	39.271	0.000	7.651	4.049-14.458		
Time from symptom onset to surgery (days)	0.760	0.343	4.890	0.027	2.137	1.090-4.190		
Chronic diarrhea	0.920	0.369	6.203	0.013	2.508	1.216-5.173		
Anesthesia method of perianal abscess	0.836	0.288	8.436	0.004	2.308	1.313-4.059		

did not progress to form an anal fistula during the follow-up period. This could be due to a small proportion of FPAs undergoing a reversal of fistulogenic tendency or errors in classification from clinical or imaging assessments, which resulted in the misclassification of patients, who would have belonged to the NFPA group, into the FPA group. This suggests that the accuracy of the classification system required continuous improvement.

Consistent with the previous findings[14], we also found that patients with a time  $\geq$  7 days from symptom onset to surgery were more likely to relapse than those with a time < 7 days ( $\chi^2 =$  74.940, OR = 2.137). A substantial proportion of these patients were in the FPA group, suggesting that prolonged inflammation may progressively compromise the local barrier function. Thus, FPA appears to be an intermediate stage between abscess and fistula, indicating that timely I and D is essential to prevent postoperative recurrence.

In contrast to two previous studies [17,18], we found that chronic diarrhea was a predisposing factor for anorectal abscess recurrence ( $\chi^2 = 27.242$ , OR = 2.508). Chronic diarrhea is often associated with intestinal flora dysbiosis [19]. Anorectal abscesses are caused mainly by bacterial infection [20] and are associated with the gut microbiota [21]. Significant differences exist in the diversity and abundance of gut microbiota between healthy individuals and patients with perianal abscesses [22]. Based on this observation, it is plausible to hypothesize that intestinal flora dysbiosis plays an essential role in the occurrence and recurrence of anorectal abscesses by possibly depleting the protective mucin of the anal glands, thereby damaging the local barrier. Therefore, it is meaningful to intervene and regulate the intestinal flora postoperatively to prevent recurrence in patients with anorectal abscess and chronic diarrhea.

Furthermore, anorectal abscesses drained in the operating room have a lower recurrence rate[23]. Our study yielded similar results; patients who underwent surgery under local anesthesia on an outpatient basis had a recurrence rate more than 2-fold higher than those who received spinal anesthesia on an inpatient basis ( $\chi^2 = 8.305$ , OR = 2.308). This may be because, compared to local anesthesia, spinal anesthesia provides fuller exposure, more thorough drainage, and a lower likelihood of residual inflammation. Based on this finding, we recommend that patients with anorectal abscesses should be hospitalized and operated on under spinal anesthesia.

Notably, the postoperative recurrence rate of intersphincteric abscesses is significantly lower than those of the other classifications, contrary to this study[24]. We performed partial internal sphincterotomy to drain intersphincteric abscesses endoanally or transrectally. The only healed supralevator abscess was treated with an internal sphincterotomy, which corroborates that the deep posterior intersphincteric space plays a vital role in developing and managing cryptoglandular fistula[25]. It can be surmised that the internal sphincter acts as a barrier role here, and the post-internal sphincterotomy recovery period can be viewed as a process of barrier reconstruction. Given the non-dominant role of the internal anal sphincter in anal continence, we advocate that in anorectal abscesses with incomplete internal anal sphincter, incision of the involved internal sphincter is beneficial in preventing postoperative recurrence.

The impact of postoperative antibiotic use on subsequent fistula formation in patients with anorectal abscesses has been studied in a series of studies with disparate results[24,26]. Nonetheless, preoperative antibiotic use has rarely been evaluated previously. Our study showed that this variable was a risk factor for postoperative recurrence ( $\chi^2$  = 18.565), although it was not significant in multivariate logistic regression analysis. In today's society, with the use of the internet and social media, many patients self-diagnose and self-medicate. Additionally, it is relatively easy to obtain antibiotics in China. Consequently, patients only seek medical care when their self-treatment is ineffective. It is our view that these patients tended to have a more extended period from symptom onset to seeking medical advice, which may explain the higher rate of postoperative recurrence in patients who had used antibiotics preoperatively. While these antibiotics may be helpful for symptom relief, they may increase the risk of postoperative recurrence. Therefore, future research should investigate how the preoperative use of antibiotics affects the prognosis of patients with anorectal abscesses.

We found that patients with pus culture results of *Escherichia coli* and *Klebsiella pneumoniae* were more prone to recurrence than those with *Staphylococcus aureus* (*S. aureus*), which supports previous findings[9,27]. Interestingly, 18 of 19 patients with *S. aureus* positive pus culture were cured, and all these patients had diabetes mellitus; the only one who relapsed did not have diabetes mellitus. Our study had similar observations to this one[13]. Diabetes mellitus may be a contributory factor for the development of anorectal abscesses; however, it seems to be a protective factor for recurrence. For patients with diabetes mellitus, we routinely monitored blood glucose levels and consulted an endocrinologist for glucose control. We analyzed the probable cause of this phenomenon: Patients with anorectal abscesses arising from poor glycemic control were strictly controlled for blood sugar postoperatively. Furthermore, it is also possible that patients with diabetes mellitus that have anorectal abscesses have different pathogenesis compared to other patients. It is essential to examine the mechanism of the effect of diabetes mellitus on patients with anorectal abscesses.

Several previous studies have yielded different results regarding BMI as a potential risk factor for postoperative recurrence of anorectal abscesses[17,23]. In our study, when analyzed in all patients, the recurrence rate was higher in the group with a BMI  $\geq$  28 than in the group with BMI < 28, although statistical significance was not reached. When BMI was

Raishideng® WJGS | https://www.wjgnet.com

Variables	Total ( <i>n</i> = 383)	Recurrence ( <i>n</i> = 90) (23.5%)	Cured ( <i>n</i> = 293) (76.5%)	X <sup>2</sup>	P value
Gender		. , , , ,		<u></u>	
Male	346	86 (24.9)	260 (75.1)	3.668	0.055
Female	37	4 (10.8)	33 (89.2)		
Age (years)					
< 20	5	1 (20.0)	4 (80.0)		
20-29	88	22 (25.0)	66 (75.0)		
30-39	95	24 (25.3)	71 (74.7)	2.580	0.764
40-49	88	22 (25.0)	66 (75.0)		
50-59	87	19 (21.8)	68 (78.2)		
> 60	20	2 (10.0)	18 (90.0)		
Body mass index (kg/m <sup>2</sup> )					
< 28	312	66 (21.2)	246 (78.8)	5.148	0.023
≥28	71	24 (33.8)	47 (66.2)		
Time from symptom onset to surgery(days)					
<7	342	66 (19.3)	276 (80.7)	31.356	< 0.001
≥7	41	24 (58.5)	17 (41.5)		
Smoking status					
Smoker	93	24 (25.8)	69 (74.2)	0.364	0.546
Non smoker	290	66 (22.8)	224 (77.2)		
Drinking habit					
Yes	64	20 (31.3)	44 (68.7)	2.568	0.109
No	319	70 (21.9)	249 (78.1)		
Spicy food habit					
Yes	116	31 (26.7)	85 (73.3)	0.963	0.326
No	267	59 (22.1)	208 (77.9)		
Diabetes mellitus					
Yes	46	8 (17.4)	38 (82.6)	1.085	0.298
No	337	82 (24.3)	255 (75.7)		
Fever					
Yes	78	15 (19.2)	63 (80.8)	0.992	0.319
No	305	75 (24.6)	230 (75.4)		
Preoperative antibiotic use					
Yes	119	24 (20.2)	95 (79.8)	1.065	0.302
No	264	66 (25.0)	198 (75.0)		
Constipation					
Yes	31	8 (25.8)	23 (74.2)	0.100	0.752
No	352	82 (23.3)	270 (76.7)		
Chronic diarrhea					
Yes	58	27 (46.6)	31 (53.4)	20.206	< 0.001
No	325	63 (19.4)	262 (80.6)		
Insomnia					

#### Chen SZ et al. A new classification of anorectal abscesses

Yes	59	15 (25.4)	44 (74.6)	0.144	0.705
No	324	75 (23.1)	249 (76.9)		
Anesthesia method of perianal abscess					
Local	132	36 (27.3)	96 (72.7)	7.191	0.007
Spinal	107	14 (13.1)	93 (86.9)		
Abscess site					
Anterior	12	2 (16.7)	10 (83.3)	2.062	0.560
Posterior	189	38 (20.1)	151 (79.9)		
Left	71	15 (21.1)	56 (78.9)		
Right	92	25 (27.2)	67 (72.8)		
Anatomic classification					
Perianal	239	50 (20.9)	189 (79.1)	40.211	< 0.001
Intersphincteric	73	5 (6.8)	68 (93.2)		
Ischiorectal	52	25 (48.1)	27 (51.9)		
Horseshoe	18	10 (55.6)	8 (44.4)		
Supralevator	1	0 (0.0)	1 (100.0)		
Pus volume (mL)					
< 5	253	52 (20.6)	201 (79.4)	3.597	0.058
≥5	130	38 (29.2)	92 (70.8)		
Pus culture					
With results	158	36 (22.8)	122 (77.2)	3.760	0.452
Escherichia coli	99	26 (26.3)	73 (73.7)		
Klebsiella pneumoniae	26	5 (19.2)	21 (80.8)		
Staphylococcus aureus	17	1 (5.9)	16 (94.1)		
Others	16	4 (25.0)	12 (75.0)		
No growth	225	54 (24.0)	171 (76.0)		

#### Table 5 Variable assignment table of risk factors in non-fistula-prone abscess subgroup

Variables	Assignment
Postoperative prognosis	1: Recurrence, 0: Cured
Body mass index	1: ≥ 28, 0: < 28
Time from symptom onset to surgery(days)	1:≥7, 0:<7
Pus volume	1: ≥ 5, 0: < 5
Chronic diarrhea	1: Yes, 0: No
Anesthesia method of perianal abscess	1: Local, 0: Spinal
Anatomic classification	1: Perianal, 2: Intersphincteric, 3: Ischiorectal, 4: Horseshoe, 5: Supralevator

analyzed in the NFPA subgroup; BMI  $\geq$  28 was a risk factor for relapse in both the univariate and multivariate logistic regression analysis. This may be due to the control of some confounding factors through stratification. This suggests that special attention should be paid to postoperative follow-up of obese patients in the NFPA group.

Furthermore, our study indicated that sex, age, pus volume, smoking status, drinking and spicy food habits, fever, constipation, insomnia, and abscess site were not associated with the postoperative recurrence of anorectal abscesses.

Our study has several strengths, including: (1) The inclusion of a large population of patients with anorectal abscesses over a relatively long period; (2) The relatively comprehensive risk factors analyzed; and (3) To the best of our knowledge, this is the first study dedicated to the classification of anorectal abscesses according to their propensity to develop into fistulas, which is expected to shed some light on this issue.



Baisbideng® WJGS | https://www.wjgnet.com

Table 6 A multivariate logistic regression analysis of risk factors for postoperative recurrence in non-fistula-prone abscess subgroup						
Variables	B value	SE	Wald	P value	Odds ratio	95%CI
Body mass index	1.077	0.455	5.593	0.018	2.935	1.203-7.165
Time from symptom onset to surgery (days)	1.788	0.548	10.659	0.001	5.978	2.043-17.489
Chronic diarrhea	1.229	0.460	7.144	0.008	3.417	1.388-8.412
Anesthesia method of perianal abscess	1.206	0.387	9.721	0.002	3.341	1.565-7.133

However, this study had some limitations: (1) The retrospective nature of the study makes it difficult to ensure complete accuracy of the clinical data of some patients; (2) The generalizability of our study is potentially limited, given that this was a single-center study; and (3) Some cases that recurred after one year may be missed due to the relatively short follow-up period (one year).

A future multicenter prospective randomized clinical trial is essential to compare different surgical procedures for FPAs or NFPAs. Additionally, the pathophysiological, immunological, and microbiological differences between FPAs and NFPAs deserve to be studied, which may yield biomarkers that help predict the postoperative recurrence of anorectal abscesses.

#### CONCLUSION

The new classification of anorectal abscesses proposed in this study is a reliable predictor of postoperative recurrence, and can be effectively used by anorectal surgeons. It provides specific guidance for selecting surgical procedure: For NFPAs, I and D alone is recommended; for FPAs, concurrent fistulotomy or seton placement can be attempted, and prompt and thorough I and D can significantly reduce postoperative recurrence. Furthermore, attention should to be paid to regulating the intestinal flora in patients with chronic diarrhea and closely monitoring obese patients postoperatively.

#### FOOTNOTES

Author contributions: Chen SZ and Shi RJ designed the research study; Chen SZ and Sun KJ performed the surgeries; Chen SZ, Gu YF and Zhao HY conducted follow-ups, collected the data, and drafted the article; Shi RJ and Sun KJ analyzed the data and made critical revisions to the article; Wang D performed the ultrasound reading; Shi YF performed the magnetic resonance imaging reading; all authors have read and approved the final manuscript.

Supported by The Zhenjiang City Key Research and Development Plan Social Development, China, No. SH2023047.

Institutional review board statement: This study was reviewed and approved by the Ethics Committee of Yangzhong People's Hospital, No. KY202317.

Informed consent statement: The requirement for written informed consent was waived due to its retrospective and anonymous nature of this study.

Conflict-of-interest statement: All authors declare no conflicts of interest related to the study.

Data sharing statement: Data from this study can be obtained from the corresponding author on reasonable request.

STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country of origin: China

ORCID number: Shan-Zhong Chen 0009-0002-3891-6519; Kui-Jun Sun 0009-0005-5936-484X; Yi-Fan Gu 0000-0001-5789-7099; Hong-Yuan Zhao 0009-0009-8523-8539; Dong Wang 0009-0005-0661-3312; Yun-Fang Shi 0009-0007-5648-0743; Ren-Jie Shi 0009-0006-5932-0959.

S-Editor: Luo ML L-Editor: A P-Editor: Xu ZH



WJGS | https://www.wjgnet.com

#### REFERENCES

- Abcarian H. Anorectal infection: abscess-fistula. Clin Colon Rectal Surg 2011; 24: 14-21 [PMID: 22379401 DOI: 10.1055/s-0031-1272819]
- Pearce L, Newton K, Smith SR, Barrow P, Smith J, Hancock L, Kirwan CC, Hill J; North West Research Collaborative. Multicentre observational study of outcomes after drainage of acute perianal abscess. *Br J Surg* 2016; 103: 1063-1068 [PMID: 27061287 DOI: 10.1002/bjs.10154]
- 3 Lohsiriwat V. Anorectal emergencies. World J Gastroenterol 2016; 22: 5867-5878 [PMID: 27468181 DOI: 10.3748/wjg.v22.i26.5867]
- 4 Ho YH, Tan M, Chui CH, Leong A, Eu KW, Seow-Choen F. Randomized controlled trial of primary fistulotomy with drainage alone for perianal abscesses. *Dis Colon Rectum* 1997; 40: 1435-1438 [PMID: 9407981 DOI: 10.1007/BF02070708]
- 5 Ramanujam PS, Prasad ML, Abcarian H, Tan AB. Perianal abscesses and fistulas. A study of 1023 patients. *Dis Colon Rectum* 1984; 27: 593-597 [PMID: 6468199 DOI: 10.1007/BF02553848]
- 6 Cox SW, Senagore AJ, Luchtefeld MA, Mazier WP. Outcome after incision and drainage with fistulotomy for ischiorectal abscess. Am Surg 1997; 63: 686-689 [PMID: 9247434]
- 7 Tang CL, Chew SP, Seow-Choen F. Prospective randomized trial of drainage alone vs. drainage and fistulotomy for acute perianal abscesses with proven internal opening. *Dis Colon Rectum* 1996; **39**: 1415-1417 [PMID: 8969668 DOI: 10.1007/BF02054531]
- 8 Schouten WR, van Vroonhoven TJ. Treatment of anorectal abscess with or without primary fistulectomy. Results of a prospective randomized trial. *Dis Colon Rectum* 1991; **34**: 60-63 [PMID: 1991422 DOI: 10.1007/BF02050209]
- 9 Hämäläinen KP, Sainio AP. Incidence of fistulas after drainage of acute anorectal abscesses. Dis Colon Rectum 1998; 41: 1357-1361 [PMID: 9823799 DOI: 10.1007/BF02237048]
- 10 Tarasconi A, Perrone G, Davies J, Coimbra R, Moore E, Azzaroli F, Abongwa H, De Simone B, Gallo G, Rossi G, Abu-Zidan F, Agnoletti V, de'Angelis G, de'Angelis N, Ansaloni L, Baiocchi GL, Carcoforo P, Ceresoli M, Chichom-Mefire A, Di Saverio S, Gaiani F, Giuffrida M, Hecker A, Inaba K, Kelly M, Kirkpatrick A, Kluger Y, Leppäniemi A, Litvin A, Ordoñez C, Pattonieri V, Peitzman A, Pikoulis M, Sakakushev B, Sartelli M, Shelat V, Tan E, Testini M, Velmahos G, Wani I, Weber D, Biffl W, Coccolini F, Catena F. Anorectal emergencies: WSES-AAST guidelines. *World J Emerg Surg* 2021; 16: 48 [PMID: 34530908 DOI: 10.1186/s13017-021-00384-x]
- Gaertner WB, Burgess PL, Davids JS, Lightner AL, Shogan BD, Sun MY, Steele SR, Paquette IM, Feingold DL; Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Anorectal Abscess, Fistula-in-Ano, and Rectovaginal Fistula. *Dis Colon Rectum* 2022; 65: 964-985 [PMID: 35732009 DOI: 10.1097/DCR.00000000002473]
- 12 Huang X. The "Hands" teaching method for the classification of anorectal abscess. *Asian J Surg* 2024; **47**: 1093-1094 [PMID: 37996380 DOI: 10.1016/j.asjsur.2023.10.124]
- Hamadani A, Haigh PI, Liu IL, Abbas MA. Who is at risk for developing chronic anal fistula or recurrent anal sepsis after initial perianal abscess? *Dis Colon Rectum* 2009; 52: 217-221 [PMID: 19279415 DOI: 10.1007/DCR.0b013e31819a5c52]
- 14 Yano T, Asano M, Matsuda Y, Kawakami K, Nakai K, Nonaka M. Prognostic factors for recurrence following the initial drainage of an anorectal abscess. *Int J Colorectal Dis* 2010; 25: 1495-1498 [PMID: 20640431 DOI: 10.1007/s00384-010-1011-9]
- 15 Hasan ZAIY, Mohamed B, AlSayegh R, AlMarzooq R. Incidence of anal fistula after pyogenic perianal abscess drainage in Kingdom of Bahrain. Ann Coloproctol 2023; 39: 27-31 [PMID: 34376025 DOI: 10.3393/ac.2020.00962.0137]
- 16 Holzheimer RG, Siebeck M. Treatment procedures for anal fistulous cryptoglandular abscess--how to get the best results. *Eur J Med Res* 2006; 11: 501-515 [PMID: 17182363]
- 17 Lu D, Lu L, Cao B, Li Y, Cao Y, Li Z, Wang Z, Lu J. Relationship Between Body Mass Index and Recurrence/Anal Fistula Formation Following Initial Operation for Anorectal Abscess. *Med Sci Monit* 2019; 25: 7942-7950 [PMID: 31642447 DOI: 10.12659/MSM.917836]
- 18 Ding C, Chen Y, Yan J, Wang K, Tan SS. Risk factors for therapy failure after incision and drainage alone for perianal abscesses in children. Front Pediatr 2024; 12: 1342892 [PMID: 38390277 DOI: 10.3389/fped.2024.1342892]
- 19 Scaldaferri F, Pizzoferrato M, Pecere S, Forte F, Gasbarrini A. Bacterial flora as a cause or treatment of chronic diarrhea. Gastroenterol Clin North Am 2012; 41: 581-602 [PMID: 22917165 DOI: 10.1016/j.gtc.2012.06.002]
- 20 Alabbad J, Abdul Raheem F, Alkhalifa F, Hassan Y, Al-Banoun A, Alfouzan W. Retrospective Clinical and Microbiologic Analysis of Patients with Anorectal Abscess. Surg Infect (Larchmt) 2019; 20: 31-34 [PMID: 30234438 DOI: 10.1089/sur.2018.144]
- 21 Brook I. The role of anaerobic bacteria in cutaneous and soft tissue abscesses and infected cysts. *Anaerobe* 2007; 13: 171-177 [PMID: 17923425 DOI: 10.1016/j.anaerobe.2007.08.004]
- Yin H, Luo B, Wang Q, Hong Z, Chen H, Shen L, Shen B, Hu B. Differences in Gut Microbiota between Healthy Individuals and Patients with Perianal Abscess before and after Surgery. *Mediators Inflamm* 2023; 2023: 1165916 [PMID: 37091905 DOI: 10.1155/2023/1165916]
- 23 Narayanan S, Althans AR, Reitz KM, Allen LH, Kurukulasuriya C, Larkin TM, Reinert NJ, Cunningham KE, Watson AR, Celebrezze JP, Medich DS, Holder-Murray J. Drainage of anorectal abscesses in the operating room is associated with a decreased risk of abscess recurrence and fistula formation. *Am J Surg* 2023; 225: 347-351 [PMID: 36150906 DOI: 10.1016/j.amjsurg.2022.09.005]
- Sözener U, Gedik E, Kessaf Aslar A, Ergun H, Halil Elhan A, Memikoğlu O, Bulent Erkek A, Ayhan Kuzu M. Does adjuvant antibiotic treatment after drainage of anorectal abscess prevent development of anal fistulas? A randomized, placebo-controlled, double-blind, multicenter study. *Dis Colon Rectum* 2011; 54: 923-929 [PMID: 21730779 DOI: 10.1097/DCR.0b013e31821cc1f9]
- 25 Zhang H, Zhou ZY, Hu B, Liu DC, Peng H, Xie SK, Su D, Ren DL. Clinical Significance of 2 Deep Posterior Perianal Spaces to Complex Cryptoglandular Fistulas. *Dis Colon Rectum* 2016; 59: 766-774 [PMID: 27384095 DOI: 10.1097/DCR.000000000000628]
- Ghahramani L, Minaie MR, Arasteh P, Hosseini SV, Izadpanah A, Bananzadeh AM, Ahmadbeigi M, Hooshanginejad Z. Antibiotic therapy for prevention of fistula in-ano after incision and drainage of simple perianal abscess: A randomized single blind clinical trial. *Surgery* 2017; 162: 1017-1025 [PMID: 28822559 DOI: 10.1016/j.surg.2017.07.001]
- 27 Toyonaga T, Matsushima M, Tanaka Y, Shimojima Y, Matsumura N, Kannyama H, Nozawa M, Hatakeyama T, Suzuki K, Yanagita K, Tanaka M. Microbiological analysis and endoanal ultrasonography for diagnosis of anal fistula in acute anorectal sepsis. *Int J Colorectal Dis* 2007; 22: 209-213 [PMID: 16601946 DOI: 10.1007/s00384-006-0121-x]

Saisbideng® WJGS | https://www.wjgnet.com



### Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: office@baishideng.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

